Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
|
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report
    Wang, W.
    Xu, C.
    Zhu, Y.
    Liao, X.
    Zhuang, W.
    Du, K.
    Chen, R.
    Chen, Y.
    Chen, G.
    Fang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2244 - S2244
  • [12] ROS 1 Rearrangement in a adenosquamous NSCLC and near CR with Crizotinib: A case report
    Griesinger, F.
    Falk, M.
    Henke, R-P
    Halbfass, V
    Conradi, I
    Hallas, C.
    Tiemann, M.
    ONKOLOGIE, 2013, 36 : 253 - 253
  • [13] Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
    Zhu, You-cai
    Liao, Xing-hui
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Zhong, Li-hua
    Du, Kai-qi
    Chen, Yan-ping
    Chen, Gang
    Fang, Mei-yu
    ONCOTARGETS AND THERAPY, 2017, 10 : 3187 - 3192
  • [14] Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report
    Campos-Gomez, Saul
    Lara-Guerra, Humberto
    Routbort, Mark J.
    Lu, Xinyan
    Simon, George R.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (02): : E254 - E257
  • [15] Lung adenocarcinoma with ROS1 rearrangement presenting with bilateral organizing pneumonia: a case report
    Aslam, S.
    Jeffs, Y.
    Jessop, S.
    Collins, S.
    Azher, M.
    Thomas, E.
    Gillespie, L.
    Barclay, C.
    Vohra, V.
    Maidment, G.
    Bulusu, V. R.
    LUNG CANCER, 2019, 127 : S95 - S95
  • [16] Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures
    Deng, Huiyan
    Liu, Chang
    Zhang, Guoliang
    Wang, Xiaoling
    Liu, Yueping
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (12) : 2103 - 2105
  • [17] Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
    Yongchang Zhang
    Zhe Huang
    Liang Zeng
    Xiangyu Zhang
    Yizhi Li
    Qinqin Xu
    Haiyan Yang
    Analyn Lizaso
    Chunwei Xu
    Jun Liu
    Wenxian Wang
    Zhengbo Song
    Sai-Hong Ignatius Ou
    Nong Yang
    npj Precision Oncology, 6
  • [18] Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
    Zhang, Yongchang
    Huang, Zhe
    Zeng, Liang
    Zhang, Xiangyu
    Li, Yizhi
    Xu, Qinqin
    Yang, Haiyan
    Lizaso, Analyn
    Xu, Chunwei
    Liu, Jun
    Wang, Wenxian
    Song, Zhengbo
    Ou, Sai-Hong Ignatius
    Yang, Nong
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [19] Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
    Lin, YunYu
    Lei, Yan
    Li, LinWei
    Su, Xiaoxing
    Tian, Qiqi
    Wu, Wendy
    ONCOTARGETS AND THERAPY, 2022, 15 : 831 - 836
  • [20] Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
    Xu, Chun-wei
    Wang, Wen-xian
    Huang, Rong-fang
    He, Cheng
    Liao, Xing-hui
    Zhu, You-cai
    Du, Kai-qi
    Zhuang, Wu
    Chen, Yan-ping
    Chen, Gang
    Fang, Mei-yu
    THORACIC CANCER, 2017, 8 (06) : 714 - 719
12345